Reteplase: Difference between revisions
Ahmed Zaghw (talk | contribs) No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
==Overview== | ==Overview== | ||
'''Reteplase''' (trade names '''Retavase''', '''Rapilysin''') is a [[thrombolytic drug]], used to treat [[myocardial infarction|heart attacks]] by breaking up the [[clot]]s that cause them. | |||
Reteplase is a recombinant non-glycosylated form of human [[tissue plasminogen activator]], which has been modified to contain 357 of the 527 [[amino acid]]s of the original [[protein]]. It is produced in the [[bacterium]] [[Escherichia coli]].{{citation needed|date=December 2013}} | |||
Reteplase is similar to recombinant human tissue plasminogen activator ([[alteplase]]), but the modifications give reteplase a longer [[half-life]] of 13–16 minutes. Reteplase also binds [[fibrin]] with lower affinity than alteplase, improving its ability to penetrate into clots. | |||
Reteplase was approved by the [[Food and Drug Administration]] in 1996. | |||
==Category== | ==Category== | ||
[[Thrombolytics]], tissue plasminogen activators. | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
| Line 18: | Line 25: | ||
'''| [[Reteplase dosage forms and strengths|Dosage Forms and Strengths]]''' | '''| [[Reteplase dosage forms and strengths|Dosage Forms and Strengths]]''' | ||
'''| [[Reteplase contraindications|Contraindications]]''' | '''| [[Reteplase contraindications|Contraindications]]''' | ||
'''| [[Reteplase warnings|Warnings and Precautions]]''' | '''| [[Reteplase warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[Reteplase adverse reactions|Adverse Reactions]]''' | '''| [[Reteplase adverse reactions|Adverse Reactions]]''' | ||
'''| [[Reteplase drug interactions|Drug Interactions]]''' | '''| [[Reteplase drug interactions|Drug Interactions]]''' | ||
Revision as of 05:05, 4 March 2014
| Reteplase |
|---|
| Retavase® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Reteplase |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information, click here. Synonyms / Brand Names: Retavase®
Overview
Reteplase (trade names Retavase, Rapilysin) is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.
Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli.[citation needed]
Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.
Reteplase was approved by the Food and Drug Administration in 1996.
Category
Thrombolytics, tissue plasminogen activators.
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages